Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

Mariano Provencio-Pulla,Ernest Nadal-Alforja,Manuel Cobo,Amelia Insa,Marinha Costa Rivas,M. Majem,Delvys Rodriguez Abreu,Guillermo Lopez-Vivanco,Manuel Domine,Elvira del Barco Morillo,Bartomeu Massuti,Rosario Garcia Campelo,Alexandre Martinez Marti,R. M. Bernabé,Fernando Franco,Maria Jove,Ricardo Arrabal,Paloma Martín,J. Casal,Virginia Calvo

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

2018

8521Background: The combination of chemotherapy and immunotherapy (CT-IO) has a high response rate and longer survival in unselected patients (pts) with metastatic non-small cell lung cancer (NSCLC...

Keywords:

Cell
non-small cell lung cancer (NSCLC)
Oncology
Immunotherapy
Response rate (survey)
Pathology
Lung cancer
Chemotherapy
Internal medicine
Medicine
non small cell
chemo immunotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations